A Nature study identifies a new angle on one of ovarian cancer’s hardest problems
A team led by scientists at The Wistar Institute has identified a metabolic pathway that appears to help some ovarian cancers survive platinum-based chemotherapy, a finding that could open a new route for treating tumors that have long resisted standard care. The work, published in Nature, focuses on ovarian cancers that remain proficient at repairing DNA damage. Those tumors can often withstand chemotherapy designed to kill them by overwhelming their genomes with damage, leaving patients with poor prognoses and frequent recurrence.
The central finding is that alpha-ketoglutarate, or aKG, accumulates in these DNA repair-proficient ovarian tumors and plays a key role in helping cancer cells keep repairing DNA after treatment. The researchers say they have now linked that process to an enzyme called TMLHE, identifying what they describe as a previously unrecognized metabolic mechanism behind chemotherapy resistance. Just as important, they say the discovery points to an existing drug that could inhibit the pathway and potentially make resistant tumors vulnerable again.
Why this matters
Platinum chemotherapy remains a foundational treatment across several cancers, including ovarian cancer, because DNA damage is normally lethal to fast-dividing tumor cells. But a subset of ovarian tumors can blunt that effect by restoring or maintaining DNA repair capacity. In practical terms, that means clinicians can use intensive treatment and still see disease return within months. The new study matters because it shifts attention away from DNA repair as a purely genetic or protein-signaling problem and toward metabolism as an active participant in resistance.
Senior author Katherine Aird of The Wistar Institute said these ovarian cancers are especially difficult because clinicians already throw an extensive range of treatments at them and outcomes are still poor. The new work suggests that the metabolic state of the cell is not just background chemistry. It may be helping determine whether chemotherapy succeeds or fails.
What the researchers found
- The study found that aKG accumulates in ovarian tumors that are proficient at DNA repair.
- The team confirmed that aKG helps cancer cells repair DNA and survive chemotherapy.
- Using a CRISPR-based screening approach, the researchers identified TMLHE as the relevant enzyme in the process.
- The findings challenge the long-standing tendency to focus on aKG mainly through its role in demethylation.
- The paper also points to an existing drug as a possible way to inhibit the pathway.
The TMLHE result is notable because it reframes how researchers may think about aKG in cancer biology. According to the study summary, work on this metabolite across multiple fields has often emphasized its involvement in removing methyl groups from proteins and other molecules. Instead, this team traced the resistance effect to the enzyme that initiates the body’s own synthesis of carnitine. That gives the finding both mechanistic weight and translational relevance: it is not just an association, but a candidate intervention point.
What comes next
The study does not mean a new treatment is ready for patients tomorrow. What it does provide is a more concrete map for the next stage of drug development and combination testing. If the pathway can be blocked safely and effectively, researchers may be able to pair that strategy with platinum chemotherapy in patients whose tumors would otherwise repair the damage and continue growing.
That possibility is significant because resistant ovarian cancer remains a persistent clinical challenge. Even incremental gains can matter when recurrence happens quickly and treatment options narrow. A target tied to tumor metabolism also raises the prospect of biomarker-driven care: if clinicians can identify tumors with elevated aKG or pathway activity, they may eventually be able to select patients more precisely for a resistance-breaking strategy.
For now, the study’s immediate importance is conceptual as much as therapeutic. It argues that chemotherapy resistance in ovarian cancer is not only a story about DNA repair genes but also about the metabolic conditions that enable repair to continue. That is a useful shift for a field still looking for better ways to extend the benefit of existing drugs.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
